Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
about
Affinity and avidity in antibody-based tumor targetingNext generation of antibody therapy for cancer.Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathwaysDesign and applications of bispecific heterodimers: molecular imaging and beyondERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Optimal multivalent targeting of membranes with many distinct receptorsChemical generation of bispecific antibodies.Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityInhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversificationHER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsCombining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesHybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers.Affibody-mediated PET imaging of HER3 expression in malignant tumours.A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cellsCross-arm binding efficiency of an EGFR x c-Met bispecific antibody.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Self-assembled antibody multimers through peptide nucleic acid conjugation.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsResearch and development of next generation of antibody-based therapeuticsPharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.Immunotherapy for breast cancer: past, present, and future.Ligand-inducible dimeric antibody for selecting antibodies against a membrane protein based on mammalian cell proliferation.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli.Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Insights into the molecular basis of a bispecific antibody's target selectivity.A semi high-throughput method for screening small bispecific antibodies with high cytotoxicityBalancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.Exploiting Receptor Competition to Enhance Nanoparticle Binding Selectivity.
P2860
Q24613552-9E75D875-792A-4811-A895-86C7EA1AFF0BQ33579636-35A02BF5-F7D4-4065-9448-771F6A2D6C0CQ33584432-8C160FC2-F0C5-4B49-8790-C6779105F704Q33732587-BE13E0FA-A1A7-4D2C-8B7C-4C6742ED8671Q33772914-BEC384CA-6951-421E-8E41-657DF34EA2D9Q33913650-5694B309-30BF-4BA2-8504-D4A91420994DQ34450000-8353A1B7-AA3D-4D9F-8ED1-30E2220A9BE3Q34575855-815C8C78-FB18-43DA-A295-5F60D38AC54CQ34722687-81B24B37-E91F-46E6-874B-97DA59CE2ED1Q35201923-9DBC109E-67A1-40DA-B78D-D82D195DA45AQ35409548-6AC28EE8-D763-45B2-8E8A-D9680E09986AQ36060512-A643FF8A-8CE0-4D0D-AA70-A74C1D9B183AQ36174716-FBB14C0C-DDC2-439C-81E1-10C5CD9484DBQ36216038-EE5D968A-6370-4BBC-B988-211366EAC1BAQ37287006-ED9C0CEA-7B00-42F2-A12E-1F7D75F72BC3Q37593702-8707416D-1F05-4FCC-92C1-78DDC7699826Q37633102-0E837240-DC51-4645-8D44-CA3C55533184Q37698914-7C88112C-9E27-49D0-8C7D-137512FF2B17Q37778732-8F1093F9-250E-47F1-8347-2257339E9661Q38072598-C245786D-6C01-4872-BC85-D60DB6096930Q38364887-D544A2F9-BA90-4B09-A9C8-E4215971E5FDQ38787696-6086B9E5-BA62-44F8-B930-89A1A4A1EB2EQ38826849-3FEEC0BC-F311-4E82-B8A8-02EC8D6C47E3Q38929801-C57B91C1-423D-4F34-9239-741CDA33040DQ39010656-51604C1F-17C2-4038-96D6-CA4BDA3E4B22Q39011393-D765E62D-33A3-4DBC-8445-1520E89872CCQ39016180-66F91CA5-A5D5-4C3F-BFFB-BC0658B32E8AQ39341721-26597F8E-85D6-4CC1-89E7-6D00DAC94761Q39397717-108931B2-EE3C-4E51-B01B-1E94806E46FBQ39974009-7AED9C9A-FEBD-45F7-B568-A2E769A3BA4AQ40971778-00BAACA2-A998-4947-893F-C1D2BF916411Q41946862-C06702D6-3E31-4FBF-B301-1FC9C4CE0111Q42128614-046C962C-C378-4120-B286-F347BD34F8E8Q42499937-3D37A7F8-37AA-4AF2-9900-3FFACFDE1634Q42732010-9B6FAF59-769D-4D21-907B-05D50491C9F1Q42854245-3B52F119-6B1F-40AC-96CE-8416A866AC1DQ45217290-05105A8C-1BD2-4EF8-BE3E-F03FAE8D62D7Q46702724-4B28A179-72A8-4BC8-8B72-0722826CA733Q47691851-A548F4B5-B16A-4A2E-B8EE-3FE1A1F93987Q50991342-B634841B-0FBE-4CF7-B1C9-8AB4AD701AF9
P2860
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@en
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@nl
type
label
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@en
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@nl
prefLabel
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@en
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@nl
P2093
P2860
P356
P1476
Targeting ErbB2 and ErbB3 with ...... a therapeutic effect in vitro.
@en
P2093
A L Sundberg
C C Shaller
H H Simmons
I Shchaveleva
M K Robinson
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604700
P407
P577
2008-10-07T00:00:00Z